Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;62(10):881-885.
doi: 10.1111/jsap.13387. Epub 2021 Jun 16.

Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020)

V Merino-Gutierrez  1 , J F Borrego  2 , J Puig  1 , A Hernández  3 , F Clemente-Vicario  1   3   4
Affiliations

Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020)

V Merino-Gutierrez et al. J Small Anim Pract. 2021 Oct.

Abstract

Objective: To determine the median survival time (MST) of dogs with nasal carcinoma treated with toceranib phosphate.

Material and methods: The databases of four Spanish referral hospitals were retrospectively searched for dogs with a diagnosis of nasal tumours presented between January 2015 and October 2020. Dogs treated with radiotherapy or other chemotherapies prior toceranib were excluded.

Results: Twenty-three dogs with a confirmed nasal carcinoma treated with toceranib phosphate and with a CT scan for initial staging according to Adams Modified Staging System were included. Nine dogs had a stage III nasal carcinoma whereas 14 dogs had a stage IV nasal carcinoma. No dog had stages I and II nasal carcinoma. The median overall survival time was 139 days. The difference between the MST between dogs with stages III and IV was not statistically significant [P = 0.6, 140 days for stage III (range 46-401) vs 120 days for stage IV (range 23-600)]. Overall, dogs with epistaxis achieved a longer median survival (166 days) than dogs without epistaxis (83 days). Toceranib phosphate was generally well tolerated. Most dogs had an initial clinical benefit followed by progressive disease.

Significance: This is the first study to report the MST in dogs with stages III and IV nasal carcinoma treated with toceranib phosphate. This retrospective study showed that toceranib phosphate decreases the clinical signs associated with nasal carcinomas.

PubMed Disclaimer

References

    1. Adams, W. M. , Kleiter, M. M. , Thrall, D. E. , et al. (2009) Prognostic significance of tumor histology and computed tomographic staging for radiation treatment response of canine nasal tumors. Veterinary Radiology & Ultrasound 50, 330-335
    1. Belshaw, Z. , Constantio-Casas, F. , Brearley, M. J. , et al. (2011) COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy. Veterinary and Comparative Oncology 9, 141-148
    1. Bernabe, L. , Portela, R. , Nguyen, S. , et al. (2013) Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Veterinary Research 9 (1), 190
    1. Gieger, T. , Rassnick, K. , Siegel, S. , et al. (2008) Palliation of clinical signs in 48 dogs with nasal carcinomas treated with coarse-fraction radiation therapy. Journal of the American Animal Hospital Association 44, 116-123
    1. Hahn, K. A. , Knapp, D. W. , Richardson, R. C. , et al. (1992) Clinical response of nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs. Journal of the American Veterinary Medical Association 200 (3), 355-357

LinkOut - more resources